PI
KRYS icon

PEAK6 Investments’s Krystal Biotech KRYS Stock Holding History

PEAK6 Investments’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1,000
Closed -$178K – 4003
2024
Q1 		$178K Buy
+1,000
New +$139K ﹤0.01% 3121

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

PEAK6 Investments's KRYS Position: Q1 2024 in Review

PEAK6 Investments sold out of Krystal Biotech (KRYS) in Q1 2024, closing a stake of 797 shares — an estimated $111K sold.

PEAK6 Investments first reported a position in KRYS in Q4 2023 and held it in 1 quarter. The position peaked at $98.9K in Q4 2023. 234 funds tracked by Wall St. Rank hold KRYS as of Q1 2024.

  • PEAK6 Investments reported no remaining Krystal Biotech position as of Q1 2024 after selling out during the quarter.
  • PEAK6 Investments sold 797 Krystal Biotech shares in Q1 2024, an estimated $111K.
  • PEAK6 Investments first reported a position in Krystal Biotech in Q4 2023 and held it in 1 quarter.
  • PEAK6 Investments's Krystal Biotech position peaked at $98.9K in Q4 2023.
  • 234 funds tracked by Wall St. Rank held Krystal Biotech as of Q1 2024.

Based on PEAK6 Investments's 13F filing for Q1 2024, filed 14 May 2024.